



23rd February 2012

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza
5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East
Mumbai 400 050

Dear Sir,

Re: Audited Financial Results for year ended 31st December 2011

We enclose herewith the Audited Financial Results of the Company for the year ended 31st December 2011. The Accounts for the said financial year were approved by the Board of Directors at its Meeting held today.

Thanking you,

Yours faithfully,
AVENTIS PHARMA LIMITED

K. SUBRAMANI
COMPANY SECRETARY

Enc :

AVENTIS PHARMA LIMITED

Registered Office: Aventis House, 54/A, Sir Mathuradas Vasarji Road, Andheri East, Mumbai 400 063

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2011

Rs. Million

Particulars	Quarter ended 31.12.2011 Audited	Quarter ended 30.09.2011 Unaudited	Quarter ended 31.12.2010 Unaudited	Year ended 31.12.2011 (Audited)	Year ended 31.12.2010 (Audited)
1.(a) Net Sales	3,379	3,127	2,865	12,297	10,850
(b) Other Operating Income	207	223	287	858	748
Total	3,586	3,350	3,072	13,153	11,598
2 Expenditure					
(a) (Increase)/decrease in stock in trade and work in progress	(70)	185	18	(75)	(120)
(b) Consumption of raw materials	1,293	1,172	1,187	4,916	4,464
(c) Purchase of traded goods	494	252	233	1,353	1,048
(d) Employees cost	503	415	455	1,784	1,533
(e) Depreciation	142	61	54	311	197
(f) Other expenditure	784	600	765	2,579	2,398
(g) Total	3,126	2,685	2,712	10,847	9,618
3 Profit from Operations before Other Income and Interest (1-2)	460	665	360	2,306	1,980
4 Other Income	80	146	136	538	389
5 Profit before Interest (3+4)	540	811	496	2,844	2,369
6 Interest	4	-	29	4	29
7 Profit before tax and Exceptional Items (5-6)	536	811	467	2,840	2,340
8 Tax expense	175	263	175	928	790
9 Net Profit for the period before Exceptional items (7-8)	361	548	292	1,912	1,550
10 Exceptional item (net of tax)	-	-	757	-	757
11 Net Profit for the period after Exceptional items (9+10)	361	548	1,049	1,912	2,307
12 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				10,761	9,748
14 Earnings Per Share (EPS) before Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	15.70	23.83	12.70	83.13	67.39
15 Earnings Per Share (EPS) after Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	15.70	23.83	45.61	83.13	100.30
16 Public Shareholding					
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60	39.60	39.60	39.60	39.60
17 Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered					
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%	60.40%

The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:

Particulars	Rs. Million	
	As at Dec 31, 2011 Audited	As at Dec 31, 2010 Audited
Shareholders' Funds :		
(a) Share capital	230	230
(b) Reserves & Surplus	10,936	9,912
(c) Deferred Tax Liabilities (Net)	85	-
TOTAL	11,251	10,142
Fixed Assets (Including Capital Work in Progress)	7,672	1,844
Investments	4	4
Deferred Tax Assets (Net)	-	99
Current Assets, Loans and Advances		
(a) Inventories	2,543	2,385
(b) Sundry Debtors	729	604
(c) Cash & Bank Balances	2,342	6,554
(d) Loans & Advances	1,671	2,567
(e) Other Current Assets	64	28
Less: Current Liabilities and Provisions		
(a) Liabilities	2,195	1,737
(b) Provisions	1,579	2,206
TOTAL	11,251	10,142

2 0 2 2

Notes:


1. The Accounts for the year ended December 31, 2011 were approved by the Board of Directors of the Company at its Meeting held on February 23, 2012.
2. The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to December 31, 2011 and the unaudited published year-to-date figures up to September 30, 2011 being the date of the end of the third quarter of the financial year.
3. The Board of Directors has recommended Final dividend of Rs.29 per Equity share of Rs.10 for the year ended December 31, 2011. An Interim dividend of Rs. 4 per Equity share of Rs.10 had been paid in August 2011. The Interim and proposed Final Dividend will together amount to a distribution of Rs. 760 million (excluding Dividend Distribution Tax) constituting 39.75% of the Company's Net Profit for the year ended December 31, 2011.
4. The Company entered into a definitive agreement, on August 24, 2011, with Universal Medicare Private Limited to acquire its business of marketing and distribution of branded nutraceutical formulations in India. The transaction was closed on November 3, 2011 on fulfillment of all the conditions precedent.
The profit for the quarter ended December 31, 2011 has been impacted due to the costs relating to the above acquisition and lower interest income as a result of the above investment.
5. The break up of Net Sales is as follows:

Rs. Million						
	Quarter ended Dec 31, 2011	Quarter ended Dec 31, 2010	Growth %	Year ended Dec 31, 2011	Year ended Dec 31, 2010	Growth %
Domestic Sales	2,788	2,240	24.5%	10,024	8,709	15.1%
Export Sales	591	625	-5.4%	2,273	2,141	6.2%
Total Sales	3,379	2,865	17.9%	12,297	10,850	13.3%

6. The Company has a single business segment namely 'Pharmaceutical Business'.
7. Information on investor complaints is furnished below:

Pending as on October 1, 2011	Received during the quarter	Disposed of during the quarter	Pending as on December 31, 2011
Nil	33	33	Nil
8. The exceptional item in the previous year relates to the sale of the entire shareholding comprising of 49,00,000 Equity shares of Rs 10 each of the Joint Venture Company, Chiron Behring Vaccines Private Limited.
9. The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED


DR. SHAILESH AYYANGAR
MANAGING DIRECTOR

February 23, 2012